Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 6/20 | 0.73 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.73 |
| ▸ | MIF | P14174 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | GABRP | O00591 | 1/20 | 0.53 |
| ▸ | GABRD | O14764 | 1/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.53 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.53 |
| ▸ | GABRE | P78334 | 1/20 | 0.53 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.53 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5365695 | 0.87 | P4HTM (0.54) | P4HTMP4HA1MIFMAPK1KDM4E | |
| SCHEMBL30269694 | 0.87 | P4HTM (0.54) | P4HTMP4HA1MIFMAPK1KDM4E | |
| Pyridine-2,5-Dicarboxylic Acid SCHEMBL70231 | 0.85 | P4HTM (1.00) | P4HTMP4HA1MIFMAPK1KDM4E | |
| Pyridine-2,5-Dicarboxylic Acid SCHEMBL29363410 | 0.85 | P4HTM (1.00) | P4HTMP4HA1MIFMAPK1KDM4E | |
| SCHEMBL28739280 | 0.84 | P4HTM (0.68) | P4HTMP4HA1MIFMAPK1KDM4E | |
| SCHEMBL1585449 | 0.83 | P4HTM (0.73) | P4HTMP4HA1MIFMAPK1KDM4E | |
| Pyridine-2,5-Dicarboxylic Acid SCHEMBL336436 | 0.83 | P4HTM (0.95) | P4HTMP4HA1MIFMAPK1KDM4E | |
| Pyridine-2,5-Dicarboxylic Acid SCHEMBL11489139 | 0.83 | P4HTM (0.95) | P4HTMP4HA1MIFMAPK1KDM4E | |
| Pyridine-2,5-Dicarboxylic Acid SCHEMBL21173963 | 0.83 | P4HTM (0.95) | P4HTMP4HA1MIFMAPK1KDM4E | |
| Pyridine-2,5-Dicarboxylic Acid SCHEMBL2275972 | 0.83 | P4HTM (0.95) | P4HTMP4HA1MIFMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779018-B2 | Heterocyclic compound and arthropod pest control composition containing same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
| US-20140315790-A1 | AMINOTHIAZOLES AND THEIR USES | BUSHELL SIMON (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2044101-B1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USES AS ANTIBACTERIAL AGENTS | NOVARTIS AG (CH) | 2013-10-09 | — | — | EP | disclosed |
| US-7655699-B1 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors | EISAI INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-20090318494-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2009-12-24 | — | — | US | disclosed |
| US-20060106072-A1 | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors | EISAI INC. | 2006-05-18 | — | — | US | disclosed |
| US-6942980-B1 | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities | ALLERGAN, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1535919-A2 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | Allergan, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-6855832-B2 | O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| WO-1997026237-A1 | AROMATIC POLYCYCLIC RETINOID-TYPE DERIVATIVES, METHOD FOR PREPARING SAME, AND USE THEREOF FOR MAKING PHARMACEUTICAL AND COSMETIC COMPOSITIONS | CENTRE EUROPEEN DE BIOPROSPECTIVE - CEB (FR) | 1997-07-24 | — | — | WO | disclosed |
| WO-1997009297-A2 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | VISION PHARMACEUTICALS L.P. (US) | 1997-03-13 | — | — | WO | disclosed |
| EP-0678086-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0678087-A1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0637297-A4 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS. | LIGAND PHARM INC (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995004036-A1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1995-02-09 | — | — | WO | disclosed |
| EP-0637297-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-02-08 | — | — | EP | disclosed |
| WO-1994015902-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1994015901-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1993021146-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106072-A1 | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors | RXRB, RXRA, RXRG | P4HTM 1383/4885P4HA1 2620/4885MIF 4404/4885 |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, PARP12, TFPI2 | P4HTM 1576/4885P4HA1 1571/4885MIF 2204/4885 |
| US-20090318494-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4B, PDE4A, PDE12 | P4HTM 1413/4885P4HA1 428/4885MIF 3262/4885 |
| US-11779018-B2 | Heterocyclic compound and arthropod pest control composition containing same | C5, PRXL2A, NOX3 | P4HTM 1873/4885P4HA1 1130/4885MIF 4764/4885 |
| US-20140315790-A1 | AMINOTHIAZOLES AND THEIR USES | ABAT, AADAT, GOT2 | P4HTM 1257/4885P4HA1 2234/4885MIF 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.